Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MIFID II May Hit Small & Midcap EU Biotech Investment

Executive Summary

New EU regulation designed to offer greater protection and more transparency for investors could have serious implications for Europe’s small to midcap biotechs just as the European Investment Bank predicts a potential €40bn funding shortfall in key bioclusters by 2021.

You may also be interested in...

Europe Needs More Patient Capital To Nurture Biotechs

Analysis by the European Investment Bank predicts that EU biotechs face a funding shortfall of up to €40bn by 2021. Barbara Freischem, executive director of European Biopharmaceutical Enterprises, who moderated a panel on the topic at BIO-Europe Spring 2018, talked to Scrip about initiatives that could alleviate the shortfall.

AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments

Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.

Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies

Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts